NetScientific PLC
(“NetScientific” or the “Group”)
London, UK – 16 November 2015: NetScientific PLC (AIM: NSCI.L), a transatlantic biomedical healthcare group, announces that it will today apply to admit, in total, 54,167 ordinary shares of 5p each to trading on AIM. Admission is expected on 20 November 2015 and these shares will rank pari passu with the existing ordinary shares in issue.
These shares are being subscribed for by a small number of employees who expressed an interest to the Board in acquiring shares in the Company, but who were unable to as part of the recent fundraising as they were not existing shareholders in NetScientific. None of these employees are directors of the Company. The subscription price is equal to that of the recent fundraising, announced on 1 October 2015, being 120 pence per ordinary share
On Admission, the Company’s issued share capital will comprise 51,075,695 Ordinary Shares, none of which will be held in treasury. This figure may be used by shareholders and other investors as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules
-Ends-
|
|
|
||||||||||||||||||||||||||||||||
|
Contact Details
|
|
||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||
About NetScientific
NetScientific is a transatlantic biomedical and healthcare technology group with a differentiated investment strategy focused solely on digital health, diagnostics and therapeutics. The Group’s objective is to source, fund and commercialise companies that significantly improve the lives of people with chronic diseases.
For more information, please visit the website at www.netscientific.net.
END
IOEPKPDQABDDADD